Journal of the neurological sciences · 2018
Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yeo Tianrong, Chen Zhiyong, Yong Kok Pin, Wong Patricia Yut Wan, Chai Josiah Yui Huei, Tan Kevin
Аннотация
BACKGROUND: To identify clinical and paraclinical differences between anti-voltage-gated potassium channel (VGKC)-complex seropositive patients with and without anti-leucine-rich glioma-inactivated protein 1 (LGI1)/contactin-associated protein-like 2 (CASPR2) antibodies (Abs).
METHODS: We performed a retrospective analysis of 50 anti-VGKC-complex seropositive patients from January 2013 to September 2016, and tested them for anti-LGI1/CASPR2 Abs. Comparative analysis was performed between anti-LGI1/CASPR2 seropositive and 'double negative' patients.
RESULTS: Seven patients had anti-LGI1/CASPR2 Abs while 43 patients were 'double negative' for these 2 Abs. Three 'double negative' patients had other neuronal surface Abs and were excluded from analysis. Compared to 'double negative' patients, a higher proportion of anti-LGI1/CASPR2 seropositive patients had complex partial seizures (5/7 vs 5/40; p = .003), limbic encephalitis (4/7 vs 2/40; p = .003), hippocampal imaging abnormalities (5/7 vs 3/39; p < .001), temporal epileptiform activity/electrographic seizures (4/6 vs 4/27; p = .020), tumours (3/7 vs 0/40; p = .002), and received acute immunotherapy (5/7 vs 6/40; p = .005) and maintenance immunotherapy (5/7 vs 4/40; p = .001). Anti-LGI1/CASPR2 seropositive patients had higher anti-VGKC-complex Abs levels (median 2857 pM [range 933-6730] vs 165 pM [104-1065]; p < .001). In contrast, a higher proportion of 'double negative' patients had non-specific behavioral disorders (20/40 vs 0/7; p = .015), and 13 of 40 (32.5%) had alternative organic diagnoses.
CONCLUSION: In anti-VGKC-complex seropositive patients, we identified features in patients with anti-LGI1/CASPR2 Abs distinct from 'double negative' patients, and found that 'double negative' patients were associated with non-specific clinical features and had a high rate of alternative diagnosis. These findings demonstrate the limited utility of anti-VGKC-complex Abs testing in suspected neurological autoimmunity.
METHODS: We performed a retrospective analysis of 50 anti-VGKC-complex seropositive patients from January 2013 to September 2016, and tested them for anti-LGI1/CASPR2 Abs. Comparative analysis was performed between anti-LGI1/CASPR2 seropositive and 'double negative' patients.
RESULTS: Seven patients had anti-LGI1/CASPR2 Abs while 43 patients were 'double negative' for these 2 Abs. Three 'double negative' patients had other neuronal surface Abs and were excluded from analysis. Compared to 'double negative' patients, a higher proportion of anti-LGI1/CASPR2 seropositive patients had complex partial seizures (5/7 vs 5/40; p = .003), limbic encephalitis (4/7 vs 2/40; p = .003), hippocampal imaging abnormalities (5/7 vs 3/39; p < .001), temporal epileptiform activity/electrographic seizures (4/6 vs 4/27; p = .020), tumours (3/7 vs 0/40; p = .002), and received acute immunotherapy (5/7 vs 6/40; p = .005) and maintenance immunotherapy (5/7 vs 4/40; p = .001). Anti-LGI1/CASPR2 seropositive patients had higher anti-VGKC-complex Abs levels (median 2857 pM [range 933-6730] vs 165 pM [104-1065]; p < .001). In contrast, a higher proportion of 'double negative' patients had non-specific behavioral disorders (20/40 vs 0/7; p = .015), and 13 of 40 (32.5%) had alternative organic diagnoses.
CONCLUSION: In anti-VGKC-complex seropositive patients, we identified features in patients with anti-LGI1/CASPR2 Abs distinct from 'double negative' patients, and found that 'double negative' patients were associated with non-specific clinical features and had a high rate of alternative diagnosis. These findings demonstrate the limited utility of anti-VGKC-complex Abs testing in suspected neurological autoimmunity.